Widespread dysregulation of MiRNAs by MYCN amplification and chromosomal imbalances in neuroblastoma: association of miRNA expression with survival.
MiRNAs regulate gene expression at a post-transcriptional level and their dysregulation can play major roles in the pathogenesis of many different forms of cancer, including neuroblastoma, an often fatal paediatric cancer originating from precursor cells of the sympathetic nervous system. We have analyzed a set of neuroblastoma (n = 145) that is broadly representative of the genetic subtypes of this disease for miRNA expression (430 loci by stem-loop RT qPCR) and for DNA copy number alterations (array CGH) to assess miRNA involvement in disease pathogenesis. The tumors were stratified and then randomly split into a training set (n = 96) and a validation set (n = 49) for data analysis. Thirty-seven miRNAs were significantly over- or under-expressed in MYCN amplified tumors relative to MYCN single copy tumors, indicating a potential role for the MYCN transcription factor in either the direct or indirect dysregulation of these loci. In addition, we also determined that there was a highly significant correlation between miRNA expression levels and DNA copy number, indicating a role for large-scale genomic imbalances in the dysregulation of miRNA expression. In order to directly assess whether miRNA expression was predictive of clinical outcome, we used the Random Forest classifier to identify miRNAs that were most significantly associated with poor overall patient survival and developed a 15 miRNA signature that was predictive of overall survival with 72.7% sensitivity and 86.5% specificity in the validation set of tumors. We conclude that there is widespread dysregulation of miRNA expression in neuroblastoma tumors caused by both over-expression of the MYCN transcription factor and by large-scale chromosomal imbalances. MiRNA expression patterns are also predicative of clinical outcome, highlighting the potential for miRNA mediated diagnostics and therapeutics.
Bray
Isabella
I
Department of Cancer Genetics, Royal College of Surgeons in Ireland, Dublin, Ireland.
Bryan
Kenneth
K
Prenter
Suzanne
S
Buckley
Patrick G
PG
Foley
Niamh H
NH
Murphy
Derek M
DM
Alcock
Leah
L
Mestdagh
Pieter
P
Vandesompele
Jo
J
Speleman
Frank
F
London
Wendy B
WB
McGrady
Patrick W
PW
Higgins
Desmond G
DG
O'Meara
Anne
A
O'Sullivan
Maureen
M
Stallings
Raymond L
RL
D045744:Cell Line, Tumor; D002869:Chromosome Aberrations; D016000:Cluster Analysis; D015331:Cohort Studies; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D035683:MicroRNAs / Q000378:metabolism; D000071447:N-Myc Proto-Oncogene Protein; D009423:Nervous System Neoplasms / Q000235:genetics / Q000378:metabolism; D009447:Neuroblastoma / Q000235:genetics*; D009687:Nuclear Proteins / Q000096:biosynthesis* / Q000235:genetics*; D009693:Nucleic Acid Hybridization; D015513:Oncogene Proteins / Q000096:biosynthesis* / Q000235:genetics*; D020133:Reverse Transcriptase Polymerase Chain Reaction; D012680:Sensitivity and Specificity; D017422:Sequence Analysis, DNA; D013564:Sympathetic Nervous System / Q000473:pathology; D016896:Treatment Outcome
C459801:MYCN protein, human; D035683:MicroRNAs; D000071447:N-Myc Proto-Oncogene Protein; D009687:Nuclear Proteins; D015513:Oncogene Proteins